Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice

References

• Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–85
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Feldman SR, Stern RS, et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51:704–8
   PubMed Web of Science ®Google Scholar
• Paul C, Gallini A, Archier E, et al. Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol. 2010;24:2–9
   PubMed Web of Science ®Google Scholar
• Patel V, Horn EJ, Lobosco SJ, et al. Psoriasis treatment patterns: results of a cross-sectional survey of dermatologists. J Am Acad Dermatol. 2008;58:964–9
   PubMed Web of Science ®Google Scholar
• Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280–4
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis: a systematic review. J Rheumatol. 2006;33:1447–51
   PubMed Web of Science ®Google Scholar
• Baker EL, Coleman CI, Reinhart KM, Phung OJ, Kugelman L, Chen W, White CM, Mamolo CM, Cappelleri JC, Baker WL. Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses. Dermatol Ther (Heidelb). 2012 Dec;2(1):9. doi: 10.1007/s13555-012-0009-3. Epub 2012 Jun 19. PubMed PMID: 23205332; PubMed Central PMCID: PMC3510417
   Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598–606
   PubMed Web of Science ®Google Scholar
• Saurat JH, Stingl G, Dubertret L, et al. CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558–66
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–15
   PubMed Web of Science ®Google Scholar
• Gordon K, Papp K, Poulin Y, et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66:241–5
   PubMed Web of Science ®Google Scholar
• Papp K, Okun M, Vender R. Adalimumab in the treatment of psoriasis: pooled efficacy and safety results from three pivotal studies. J Cutan Med Surg. 2009;13:S58–66
   PubMed Web of Science ®Google Scholar
• Mease PJ, Signorovitch J, Yu AP, et al. Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials. Dermatology. 2010;220:1–7
   PubMed Web of Science ®Google Scholar
• Papp KA, Signorovitch J, Ramakrishnan K, et al. Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials. Clin Drug Investig. 2011;31:51–60
   PubMed Web of Science ®Google Scholar
• Zhang Z, Schmitt J, Wozel G, Kirch W. Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials. Med Klin (Munich). 2009;104:125–36
   PubMed Web of Science ®Google Scholar
• Guenther L, Langley RG, Shear NH, et al. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004. J Cutan Med Surg. 2004;8:321–37
   PubMed Web of Science ®Google Scholar
• Puig L, Carrascosa JM, Daudén E, et al. Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents. Actas Dermosifilogr. 2009;100:386–413
   PubMedGoogle Scholar
• Turner D, Picot J, Copper K, Loveman E. Adalimumab for the treatment of psoriasis. Health Technol Assess. 2009;13:49–54
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. An assessment of adalimumab efficacy in three Phase III clinical trials using the European consensus programme criteria for psoriasis treatment goals. Br J Dermatol. 2013;168:374–80
   PubMed Web of Science ®Google Scholar
• Sola-Ortigosa J, Sánchez-Regaña M, Umbert-Millet P. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice. J Dermatol Treat. 2012;23:203–7
   PubMed Web of Science ®Google Scholar
• van Lümig PPM, van de Kerkhof PCM, Boezeman JBM, et al. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients. J Eur Acad Dermatol Venereol. 2012;27:593–600
   PubMed Web of Science ®Google Scholar
• Warren RB, Brown BC, Lavery D, Griffiths CE. Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol. 2012;163:859–62
   Web of Science ®Google Scholar
• Ryan C, Kirby B, Collins P, Rogers S. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. Clin Exp Dermatol. 2009;34:784–8
   PubMed Web of Science ®Google Scholar
• Ardigò M, Giuliani A, de Felice C, et al. Efficacy of adalimumab in plaque psoriasis: experience on 28 patients. J Drugs Dermatol. 2008;7:935–9
   PubMedGoogle Scholar
• Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol. 2007;57:269–75
   PubMed Web of Science ®Google Scholar
• Sterry W, Barker J, Boehncke WH, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004;151:3–17
   PubMed Web of Science ®Google Scholar
• Guenther L, Langley RG, Shear NH, et al. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004. J Cutan Med Surg. 2004;8:321–7
   PubMed Web of Science ®Google Scholar
• Langley RG, Ho V, Lynde C, et al. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches. J Cutan Med Surg. 2006;9:18–25
   PubMed Web of Science ®Google Scholar
• Patel V, Horn EJ, Lobosco SJ, et al. Psoriasis treatment patterns: results of a cross-sectional survey of dermatologists. J Am Acad Dermatol. 2008;58:964–9
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164:1091–6
   PubMed Web of Science ®Google Scholar